Health care expenditures of children and adults with spina bifida in a privately insured U.S. population.

BACKGROUND We provide new estimates of medical care utilization and expenditures over the lifespan for persons living with spina bifida in the United States. Updated estimates are essential for calculations of lifetime costs and for economic evaluations of prevention and management strategies for spina bifida. METHODS We analyzed data from the 2001-2003 MarketScan database on paid medical and prescription drug claims of persons covered by employer-sponsored health insurance in the United States. Medical care utilization and expenditures during 2003 were analyzed for persons with a diagnosis of spina bifida recorded during 2001-2003 who had 12 months of coverage in a fee-for-service health plan. To calculate expenditures during infancy, a separate analysis was performed for those born during 2002 with claims and expenditures data during the first 12 months of life. We compared medical expenditures for persons with and without spina bifida by age groups. RESULTS Average incremental medical expenditures comparing patients with spina bifida and those without were $41,460 per year at age 0, $14,070 at ages 1-17, $13,339 at ages 18-44, and $10,134 at ages 45-64. Children ages 1-17 years with spina bifida had average medical expenditures 13 times greater than children without spina bifida. Adults with spina bifida had average medical expenditures three to six times greater than adults without spina bifida in this privately insured population. CONCLUSIONS Although per capita medical care utilization and expenditures are highest among children, adults constitute an important and growing share of the population living with spina bifida.

[1]  P. Romano,et al.  Estimates of the economic costs of birth defects. , 1994, Inquiry : a journal of medical care organization, provision and financing.

[2]  R. Kirby,et al.  Survival of Infants With Neural Tube Defects in the Presence of Folic Acid Fortification , 2006, Pediatrics.

[3]  Matthew M Davis,et al.  Inpatient health care use among adult survivors of chronic childhood illnesses in the United States. , 2006, Archives of pediatrics & adolescent medicine.

[4]  P. Romano,et al.  Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. , 2005, American journal of public health.

[5]  O. Devine,et al.  Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[6]  P. Romano,et al.  Folic acid fortification of grain: an economic analysis. , 1995, American journal of public health.

[7]  L. Edmonds,et al.  Decline in the Prevalence of Spina Bifida and Anencephaly by Race/Ethnicity: 1995–2002 , 2005, Pediatrics.

[8]  M. Khoury,et al.  The changing epidemiology of neural tube defects. United States, 1968-1989. , 1992, American journal of diseases of children.

[9]  J. Jutai,et al.  Use of health care among adults with chronic and complex physical disabilities of childhood , 2005, Disability and rehabilitation.

[10]  P. Newacheck,et al.  A national profile of health care utilization and expenditures for children with special health care needs. , 2005, Archives of pediatrics & adolescent medicine.

[11]  Economic costs of birth defects and cerebral palsy--United States, 1992. , 1995, MMWR. Morbidity and mortality weekly report.

[12]  P. Romano,et al.  The Cost of Birth Defects: Estimates of the Value of Protection , 1996 .

[13]  G. Anderson,et al.  Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid program, fiscal year 1993. , 1997, Pediatrics.

[14]  L. Paulozzi,et al.  Survival of infants with spina bifida: a population study, 1979-94. , 2001, Paediatric and perinatal epidemiology.

[15]  P. Romano,et al.  The Half-Life of Cost-of-Illness Estimates: The Case of Spina Bifida , 2004 .